Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NGNE

+ Watchlist+ Portfolio

Neurogene Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$23.10
52-Week Range
$15.93 – $43.66
Market Cap
$479.02M
P/E (TTM)
—
EPS (TTM)
-5.03
Dividend Yield
0.00%
Advanced Metrics
Price/Book
1.35
PEG Ratio
—
Return on Equity
-38.42%
Return on Assets
-24.37%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
19.97
Debt/Equity
0.02
Total Debt
$7.55M
Free Cash Flow
$-53.29M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$126.85M

Market Snapshot

About

Neurogene Inc. is a clinical-stage biotechnology company developing gene therapies for rare neurological diseases. The company focuses on adeno-associated virus (AAV)-based gene therapies targeting conditions like Rett syndrome and other genetic neurological disorders. Neurogene uses its proprietary EXACT platform to deliver therapeutic genes directly to the central nervous system.